The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
Launched by CORDIS CORPORATION · Oct 7, 2005
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
This is an international, multicenter (up to 10 sites), nonrandomized, historically controlled study in patients with De Novo coronary artery lesions in small vessels treated with the CYPHER™ (sirolimus-eluting) stent as compared to the small vessel tercile uncoated Bx VELOCITYTM Stent patients from the SIRIUS Trial. A total of up to 100 patients will be enrolled in this study.
Patients with de novo native coronary artery lesions \>=15mm and \<=30mm in length and \>=2.25 mm to \<=2.75 mm in diameter by visual estimation will be treated with the CYPHER™ (sirolimus-eluting) stent. Patients w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS 1, 2, 3, 4) OR unstable angina pectoris (Braunwald Classification B\&C 1-2) OR patients with documented silent ischemia;
- • 2. Single treatment of de novo lesion in a small vessel (2.25 - 2.75 mm) in a major coronary artery in patients with single or multivessel disease. Patients with multiple lesions can be included if the other lesions are successfully treated prior to the treatment of the intended lesion in the small vessel.
- • 3. Target vessel diameter \>=2.25 and \<=2.75mm (by visual estimation);
- • 4. Target lesion length \>=15 and \<=30 mm.
- Exclusion Criteria:
- • 1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 24 hours or the CK and CK-MB remains above normal at the time of the treatment;
- • 2. Has unstable angina classified as Braunwald A (1, 2, 3) or B \& C 3;
- • 3. Unprotected left main coronary disease with \>=50% stenosis;
- • 4. Significant (\>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede inflow or runoff;
- • 5. Have an ostial target lesion;
- • 6. Lesion \< 2.25 or \> 2.75 mm in diameter;
- • 7. Totally occluded vessel (TIMI 0 level);
- • 8. Documented left ventricular ejection fraction £30%;
- • 9. Intention to treat the target lesion by direct stenting procedure.
About Cordis Corporation
Cordis Corporation is a leading global provider of innovative cardiovascular and endovascular solutions, dedicated to advancing the treatment of vascular diseases. With a strong emphasis on research and development, Cordis focuses on delivering high-quality medical devices that enhance patient outcomes and improve procedural efficiency. The company is committed to clinical excellence and rigorous regulatory compliance, actively engaging in clinical trials to support the safety and efficacy of its products. Through collaboration with healthcare professionals and continuous innovation, Cordis aims to address unmet medical needs and foster advancements in the field of interventional medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Bernhard Meier, MD
Principal Investigator
University of Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials